期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 58, 期 2, 页码 833-838出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01896-13
关键词
-
资金
- Cerexa, Inc.
- Forest Research Institute, Inc.
- Aires
- American Proficiency Institute (API)
- Anacor
- Astellas
- AstraZeneca
- Bayer
- bioMerieux
- Cempra
- Cerexa
- Contrafect
- Cubist
- Dipexium
- Furiex
- GlaxoSmithKline
- Johnson Johnson
- LegoChem Biosciences, Inc.
- Meiji Seika Kaisha
- Merck
- Nabriva
- Novartis
- Pfizer
- PPD Therapeutics
- Premier Research Group
- Rempex
- Rib-X Pharmaceuticals
- Seachaid
- Shionogi
- Medicines Co.
- Theravance
- Thermo-Fisher Scientific
Escherichia coli (328 isolates), Klebsiella pneumoniae (296), Klebsiella oxytoca (44), and Proteus mirabilis (33) isolates collected during 2012 from the nine U.S. census regions and displaying extended-spectrum-beta-lactamase (ESBL) phenotypes were evaluated for the presence of beta-lactamase genes, and antimicrobial susceptibility profiles were analyzed. The highest ESBL rates were noted for K. pneumoniae (16.0%, versus 4.8 to 11.9% for the other species) and in the Mid-Atlantic and West South Central census regions. CTX-M group 1 (including CTX-M-15) was detected in 303 strains and was widespread throughout the United States but was more prevalent in the West South Central, Mid-Atlantic, and East North Central regions. KPC producers (118 strains [112 K. pneumoniae strains]) were detected in all regions and were most frequent in the Mid-Atlantic region (58 strains). Thirteen KPC producers also carried blaCTX-M. SHV genes encoding ESBL activity were detected among 176 isolates. Other beta-lactamase genes observed were CTX-M group 9 (72 isolates), FOX (10), TEM ESBL (9), DHA (7), CTX-M group 2 (3), NDM-1 (2 [Colorado]), and CTX-M groups 8 and 25 (1). Additionally, 62.9% of isolates carried >= 2 beta-lactamase genes. KPC producers were highly resistant to multiple agents, but ceftazidime-avibactam (MIC50/90, 0.5/2 mu g/ml) and tigecycline (MIC50/90, 0.5/1 mu g/ml) were the most active agents tested. Overall, meropenem (MIC50, <= 0.06 mu g/ml), ceftazidime-avibactam (MIC50, 0.12 to 0.5 mu g/ml), and tigecycline (MIC50, 0.12 to 2 mu g/ml) were the most active antimicrobials when tested against this collection. NDM-1 producers were resistant to all beta-lactams tested. The diversity and increasing prevalence of beta-lactamase-producing Enterobacteriaceae have been documented, and ceftazidime-avibactam was very active against the vast majority of beta-lactamase-producing strains isolated from U.S. hospitals.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据